[PDF][PDF] 胰高血糖素样肽1 受体激动剂治疗糖尿病肾病的临床研究进展

周亭, 汪年松, 范瑛 - 世界临床药物, 2020 - jwph.com.cn
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND
… Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): …

新型降糖药物对2 型糖尿病患者的肾脏获益及应用前景

杨光燃 - 中国全科医学, 2021 - chinagp.net
… Liraglutide and renal outcomes in type 2 diabetes[J]. New Engl J Med,2017,377(9):839-848.…
Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND

糖尿病肾脏疾病治疗现状及进展

施雯, 张晓良 - 肾脏病与透析肾移植杂志, 2020 - njcndt.com
… Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary …
Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the REWIND

肠促胰素类药物的心肾保护作用和机制

杨柳, 谢红浪 - 肾脏病与透析肾移植杂志, 2022 - njcndt.com
… [27] 对REWIND 研 究进行探索性分析,将首次出现新发显性蛋白尿… kidney outcomes with
GLP⁃1 receptor agonists in patients with type 2 diabetes: a systematic review and meta⁃analysis

BMJ 快速推荐《 SGLT-2 抑制剂和GLP-1 受体激动剂治疗成人2 型糖尿病的临床实践指南》 解读

安康, 李舍予 - 中国全科医学, 2021 - chinagp.net
Dulaglutide and renal outcomes in type 2 diabetes:an exploratory analysis of the
REWIND … Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2016,375(4):…

中国成人2 型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识.

朱大龙, 赵家军 - Chinese Journal of Diabetes Mellitus, 2020 - search.ebscohost.com
… (REWIND): a double⁃blind, randomised placebo⁃controlled trial[J]. Lancet, 2019, 394(…
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND

糖尿病患者血糖波动异常与认知功能障碍关系的研究进展

张蓉, 陆丽, 王亚昕, 董文倩, 张宇… - 上海交通大学学报(医学 …, 2022 - xuebao.shsmu.edu.cn
… patients with cognitive dysfunction is still in the exploratory stage. It has been found that
some hypoglycemic drugs, such as glucagon like peptide -1 receptor agonist, can improve …